Roche forecast continued growth in 2025, with group sales expected to increase in the mid- single digit range
doi: 10.2174/138945012799499703 75 PaudelP.ShahF
Unlike many current treatments that focus primarily on glucose control, HTD-1801 is positioned as a potential cardiovascular-kidney-metabolic (CKM) therapy, aiming to improve glycemic control while also affecting lipid metabolism and inflammation through the gut-liver axis
Although the mechanisms are not yet fully understood, rodent and human studies show that GIP plays a role in the regulation of lipolysis and lipogenesis in adipose tissue, which could contribute to improved lipid homeostasis and whole body energy metabolism [23, 24]
T--1, with its unique mechanism of action, has already achieved significant results in diabetes treatment and weight management
Other names / synonyms of this treatment